More than 50% of HIV diagnoses now occur in 48 counties in the United States. Cuyahoga County, home to Cleveland, is one of ...

Hetero and Dr Reddy’s — will be funded by the Gates Foundation and Unitaid, respectively, to produce and sell the ...

A new long-acting medicine that could make preventing HIV transition might soon be even for poor countries like Uganda thanks to agreements between producers and key HIV/AIDS prevention programme ...

USAID antimalarial and HIV supplies valued at nearly $140 million were delayed in the first half of the year or not delivered ...

Cuts proposed by the Trump administration and House Republicans could drive up new HIV cases by more than 200,000 by 2030, ...

Lenacapavir, approved by the FDA in June, requires only two shots a year. US insurers don't cover it, but access will soon ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Millions more people at risk of HIV in low- and middle-income countries (LMICs) will have access to a powerful new prevention option: a low-cost, generic ...

Research published in The Lancet HIV earlier this year, experts estimated that, if purchased at scale, the cost of generic lenacapavir could range from USD 35 to USD 46 per person-year. Falling to USD ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.